Use of anacardium occidentale skin extract in preparation of hair health care composition

Through the preparation and combination of cashew film extracts and the compound, the problem of existing hair care products failing to effectively utilize natural plant ingredients is solved, and the effect of improving hair follicles and hair growth is achieved, and a natural hair health composition is provided.

WO2024240184A1PCT designated stage expired Publication Date: 2024-11-28TCI CO LTD(CN)
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/094696
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing hair care products have failed to make full use of natural plant ingredients, especially cashew film extract, to improve hair follicles health and hair growth, and there is room for improvement.

Method used

By preparing cashew membrane extract, cashew kernel membrane is extracted with water or alcoholic solvents to obtain cashew membrane extract, which is further filtered and concentrated, including epicatechin coumarate, phlogenes, and original cabbage. Compounds such as acid and naringin 7-O-(6"-O-p-coumaryl)-β-D-glucoside are used to prepare hair health compositions, improve the antioxidant power of hair follicle cells, promote hair follicle angiogenesis and Hair germination gene expression reduces hair germination gene expression.

Benefits of technology

Significantly improve the antioxidant power of hair follicle cells, increase the angiogenesis of hair follicles, promote hair growth, increase hair diameter, reduce blood MDA concentration, improve hair health, and provide a natural hair health solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024094696_28112024_PF_FP_ABST
    Figure CN2024094696_28112024_PF_FP_ABST
Patent Text Reader

Abstract

A use of an anacardium occidentale skin extract in the preparation of a hair health care composition. The anacardium occidentale skin extract is obtained by extraction of the skin of anacardium occidentale by using a solvent.
Need to check novelty before this filing date? Find Prior Art

Description

Use of cashew nut membrane extract in preparing hair health care composition Technical Field

[0001] The present invention relates to the application of cashew nuts, and particularly relates to the use of a cashew nut membrane extract in preparing a hair health care composition. Background Art

[0002] Since the rise of organic and / or natural diets, biotech companies and food manufacturers have actively invested in the research and development of natural plant-based products. To scientifically verify the health benefits of plant-based products, the analysis and efficacy evaluation of plant-based active ingredients have become key areas of product development.

[0003] The cashew nut (Anacardium occidentale) is a popular nut. The cashew tree is native to northern Brazil and is now cultivated in many tropical and subtropical regions, such as Vietnam. Cashews are rich in nutritional value, with the kernel being rich in unsaturated fatty acids, particularly monounsaturated fatty acids such as oleic acid. Cashews also contain vitamins E, K, and B6, as well as calcium, magnesium, potassium, and antioxidants.

[0004] Summary of the Invention

[0005] In the field of hair health care, people are increasingly focusing on obtaining essential nutrients from their diet to promote scalp and hair health. While numerous hair care products already exist on the market, and people are increasingly aware of the impact of dietary nutrition on hair, there is still room for improvement in meeting consumer needs. Consequently, hair-related products are attracting widespread attention and favor among consumers. Therefore, the inventors are actively researching and developing the use of cashew nuts in hair-related products.

[0006] In some embodiments, a cashew nut membrane extract is used to prepare a hair care composition. The cashew nut membrane extract is prepared by extracting cashew nut membrane with a solvent.

[0007] In some embodiments, in the extraction step, the solid-liquid ratio of the cashew nut membrane to water is 5-20:1-5, the extraction temperature is 80° C. to 90° C., and the extraction time is 80 minutes to 120 minutes.

[0008] In some embodiments, cashew nut membrane extract has the ability to increase hair follicle health.

[0009] In some embodiments, cashew nut membrane extract increases hair follicle health by enhancing the antioxidant capacity of hair follicle cells.

[0010] In some embodiments, cashew nut membrane extract increases hair follicle health by promoting hair follicle cell proliferation.

[0011] In some embodiments, the cashew nut membrane extract is at least one compound selected from the group consisting of epicatechin coumarate, phloroglucinol, protocatechuic acid, and naringenin 7-O-(6″-O-p-coumaryl)-β-D-glucoside.

[0012] In some embodiments, cashew nut membrane extract increases hair follicle health by increasing angiogenesis in the hair follicles.

[0013] In some embodiments, cashew nut membrane extract increases hair follicle health by promoting the expression of hair growth genes.

[0014] In some embodiments, cashew nut membrane extract increases hair follicle health by reducing the expression of genes that cause hair loss.

[0015] In some embodiments, cashew nut membrane extract increases hair follicle health by reducing blood MDA concentrations.

[0016] In some embodiments, cashew nut membrane extract has the ability to increase hair diameter.

[0017] In summary, according to any embodiment, the cashew nut membrane extract can be used to prepare a hair care composition. In other words, when the prepared hair care composition is applied to an individual, it can improve or enhance the health of the individual's hair, i.e., the aforementioned hair care composition has a hair care function. In some embodiments, the cashew nut membrane extract also has one or more of the following abilities: enhancing the antioxidant capacity of hair follicle cells, increasing angiogenesis in hair follicles, promoting the expression of hair growth genes, reducing the expression of hair loss genes, and increasing hair diameter. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] FIG1 is a flow chart of compound separation of cashew nut membrane extract.

[0019] Figure 2 is the hydrogen-nuclear magnetic resonance spectrum of gallic acid.

[0020] FIG3 is a hydrogen-nuclear magnetic resonance spectrum of epigallocatechin gallate.

[0021] FIG4 is a hydrogen-nuclear magnetic resonance spectrum of epicatechin gallate.

[0022] FIG5 is a hydrogen-nuclear magnetic resonance spectrum of epicatechin coumarate.

[0023] FIG6 is a hydrogen-nuclear magnetic resonance spectrum of phloroglucinol.

[0024] FIG7 is a hydrogen-nuclear magnetic resonance spectrum of protocatechuic acid.

[0025] FIG8 is a hydrogen-nuclear magnetic resonance spectrum of naringenin 7-O-(6″-O-p-coumaryl)-β-D-glucoside.

[0026] FIG9 is a bar graph showing the cell experiment results of the relative ROS generation of cashew nut membrane extract.

[0027] FIG10 is a bar graph showing the cell experiment results of the relative ROS generation of cashew nut membrane extract and its compounds.

[0028] FIG11 is a bar graph showing the cell experiment results of the relative cell proliferation rate of cashew nut membrane extract.

[0029] FIG12 is a bar graph showing the cell experiment results of the relative cell proliferation rates of cashew nut membrane extract and its compounds.

[0030] FIG13 is a bar graph showing the results of a cell experiment on the relative gene expression level (6 hours) of cashew nut membrane extract.

[0031] FIG14 is a bar graph showing the results of a cell experiment on the relative gene expression level (6 hours) of cashew nut membrane extract.

[0032] FIG15 is a bar graph showing the results of a cell experiment on the relative gene expression level (24 hours) of cashew nut membrane extract.

[0033] FIG16 is a bar graph showing the results of a cell experiment on the relative gene expression level (24 hours) of cashew nut membrane extract.

[0034] FIG17 is a bar graph showing the results of a cell experiment on the relative gene expression (48 hours) of cashew nut membrane extract.

[0035] FIG18 is a bar graph showing the results of a cell experiment on the relative gene expression level (48 hours) of cashew nut membrane extract.

[0036] FIG19 is a bar graph showing the results of a human experiment on the concentration of malondialdehyde (MDA), an antioxidant marker, in the blood at week 0, week 8, and week 12.

[0037] FIG20 is a bar graph showing the human experiment results of hair diameter measurement of subjects at week 0, week 8, and week 12.

[0038] Among them, the reference numerals are: G01: blank group G02: control group G30-G46: experimental groups P1-P14: separation part DETAILED DESCRIPTION

[0039] The following describes some specific implementations of this invention. Without departing from the spirit of this invention, this invention may be implemented in a variety of different forms, and the scope of protection should not be limited to the conditions specifically stated in the specification.

[0040] In some embodiments, the cashew nut membrane extract is obtained by subjecting the cashew nut membrane to an extraction process.

[0041] In some embodiments, the cashew membrane to be extracted is the cashew nut membrane (also known as cashew seed coat, cashew skin). The cashew nut membrane is one or a combination of the thin film, membrane, outer skin or seed shell inside the cashew fruit, hereinafter referred to as cashew membrane.

[0042] In some embodiments, during the extraction process, the cashew nut membranes may be raw materials (e.g., intact cashew nut membranes) or may be physically pre-processed to reduce the membranes to smaller sizes, such as fragments, granules, or powders. The physical pre-processing may include at least one of the following: coarse crushing, chopping, shearing, pounding, and grinding.

[0043] In some embodiments, the solvent can be water, alcohol, or a combination thereof. During the extraction process, the cashew nut membrane is extracted with the solvent at 80°C to 90°C for 80 to 120 minutes to obtain a primary extract. For example, the cashew nut membrane can be soaked in water at 85±5°C for 90 minutes to dissolve the active ingredients in the cashew nut membrane into the solvent, thereby obtaining a primary extract.

[0044] In some embodiments, during the extraction process, the weight ratio of cashew nut membrane to solvent is 5 to 20: 1 to 5. For example, the weight ratio of cashew nut membrane to water is 10:1.

[0045] In some embodiments, during the extraction process, the primary extract can be further filtered to remove the solids such as the cashew membrane after solvent extraction to obtain a cashew membrane filtrate. For example, the primary extract is filtered using a 400 mesh filter to remove fine solids. The filtered cashew membrane filtrate is then heated at 60°C ± 5°C and heated at 1 ± 0.2 kg / cm 2 The cashew membrane concentrate is concentrated under reduced pressure under a vapor pressure of 100°C until the Brix value of the solution is 8.8±0.5, and the concentration is stopped to obtain a cashew membrane concentrate. If the pH value of the cashew membrane concentrate is higher than 4.0, 0.23% malic acid can be added to lower the pH value to 3.2±0.5 to obtain a cashew membrane extract.

[0046] In some embodiments, the cashew nut membrane extract can be at least one embodiment or combination thereof, including a primary extract, a cashew nut membrane filtrate, a cashew nut membrane concentrate, or a cashew nut membrane extract adjusted with malic acid.

[0047] In some embodiments, cashew nut membrane extract can reduce blood malondialdehyde (MDA) levels. MDA in blood is a product of peroxidation caused by free radical attacks on cellular lipids. Higher MDA accumulation in the body indicates decreased antioxidant capacity. Specifically, cashew nut membrane extract can reduce blood MDA levels, thereby enhancing antioxidant capacity. Therefore, cashew nut membrane extract is suitable for preparing a composition with antioxidant properties.

[0048] In some embodiments, the aforementioned organism may be a human.

[0049] In some embodiments, cashew nut membrane extract can reduce ROS (reactive oxygen species) in vivo to reduce hair follicle cell damage. While an appropriate level of ROS is essential for normal cellular function, excessive levels can cause oxidative stress in hair follicle cells, leading to cell damage and apoptosis, impacting the normal function of hair follicles and potentially affecting the hair growth cycle and hair health. Therefore, cashew nut membrane extract is suitable for use in preparing compositions that reduce hair follicle cell damage.

[0050] In some embodiments, those skilled in the art can, through data analysis of malondialdehyde concentrations in blood and reduction of ROS in vivo, draw correlational conclusions: cashew nut membrane extract enhances the antioxidant capacity of organisms, and cashew nut membrane extract enhances the antioxidant capacity of hair follicle cells. In other words, cashew nut membrane extract can be used to prepare a hair care composition that enhances the antioxidant capacity of hair follicle cells.

[0051] In some embodiments, cashew nut membrane extract improves hair follicle health by reducing hair follicle cell damage, increasing hair follicle cell proliferation, or a combination thereof. The cashew nut membrane extract is a compound isolated from cashew nut membrane extract, comprising at least one of epicatechin coumarate, phloroglucinol, protocatechuic acid, or naringenin 7-O-(6-"-O-coumaroyl)-β-D-glucoside, or a combination thereof.

[0052] In some embodiments, the compound of the cashew nut membrane extract is gallic acid, gallocatechin, epicatechin gallate, epicatechin coumarate, phloroglucinol, protocatechuic acid, or naringenin 7-O-(6″-O-coumaroyl)-β-D-glucoside.

[0053] The causes of hair loss include both internal and external factors. External factors include lifestyle factors such as stress, irregular lifestyles, medications, diseases such as thyroid problems, and dietary factors such as malnutrition or insufficient intake. Even hairdressing practices such as perming and dyeing can cause hair problems. Internal factors primarily include genetics, the influence of dihydrotestosterone (DHT), and local microcirculatory issues. Genetic genes make scalp hair follicles more sensitive to hormones, and DHT can cause hair loss in some follicles. Poor blood circulation can also lead to hair loss due to insufficient nutrition. In some embodiments, cashew nut membrane extract has the function of improving hair follicle health to improve hair loss caused by internal factors. For example, improving hair follicle health can reduce hair follicle cell damage, increase hair follicle cell proliferation, increase hair follicle angiogenesis, promote the expression of hair growth genes, or reduce the expression of hair loss genes, or a combination thereof. Therefore, cashew nut membrane extract is suitable for preparing hair care compositions.

[0054] In some embodiments, cashew nut membrane extract can effectively increase the expression of angiogenesis genes in hair follicle cells, and the angiogenesis gene can be the VEGF gene (vascular endothelial growth factor). The protein encoded by the VEGF gene can bind to receptors (VEGF receptor, VEGFR) on the surface of vascular endothelial cells, thereby activating multiple intracellular signaling pathways such as tyrosine kinase, including but not limited to the PI3K-Akt pathway, the Ras-Raf-MEK-ERK pathway, and the Src kinase pathway, thereby promoting the process of angiogenesis, thereby promoting the delivery of nutrients for hair growth. Specifically, because the health and vitality of hair follicle cells are closely related to the supply of surrounding blood vessels, and the expression of angiogenesis genes is related to the formation and proliferation of blood vessels, cashew nut membrane extract has the ability to increase the expression of the VEGF gene by approximately 1.26 times, thereby increasing the expression of angiogenesis-related genes in hair follicle cells, promoting the proliferation and development of surrounding blood vessels, and improving the blood vessels' ability to transport nutrients, allowing hair follicle cells to obtain more nutrients, thereby promoting hair growth and health. Therefore, cashew nut membrane extract is suitable for preparing a hair care composition that increases angiogenesis in hair follicles.

[0055] In some embodiments, cashew nut membrane extract can effectively increase the expression of angiogenesis genes in hair follicle cells, and the angiogenesis gene can be the IGF-1 gene. The protein encoded by the IGF-1 gene can bind to receptors on the surface of vascular endothelial cells (IGF-1R (Insulin-like Growth Factor 1 Receptor) or IR (Insulin Receptor)). This, in turn, activates multiple intracellular signaling pathways, including tyrosine kinases, including but not limited to the PI3K-Akt pathway, the Ras-Raf-MEK-ERK pathway, and the Src kinase pathway, thereby promoting angiogenesis and thereby enhancing the delivery of nutrients for hair growth. Specifically, because the health and vitality of hair follicle cells are closely related to the supply of surrounding blood vessels, and the expression of angiogenesis genes is related to vasodilation and vascular resistance, cashew nut membrane extract can increase the expression of the IGF-1 gene by approximately 1.5 times, thereby increasing the expression of angiogenesis-related genes in hair follicle cells, promoting vasodilation, reducing vascular resistance, and improving the blood vessels' ability to transport nutrients, allowing hair follicle cells to obtain more nutrients, thereby promoting hair growth and health. Therefore, the cashew nut membrane extract is suitable for preparing a hair care composition for increasing hair follicle angiogenesis.

[0056] In some embodiments, cashew nut membrane extract can effectively promote the expression of hair growth genes, and the hair growth gene can be the KROX20 gene. The protein encoded by the KROX20 gene regulates hair follicle development, including but not limited to regulating the hair cycle, controlling hair pigment production, and promoting hair follicle formation. Cashew nut membrane extract has the ability to increase the expression of the KROX20 gene by approximately 1.93 times, thereby increasing the expression of hair growth-related genes in hair follicle cells. Therefore, cashew nut membrane extract is suitable for use in the preparation of a hair care composition that promotes the expression of hair growth genes.

[0057] In some embodiments, cashew nut membrane extract can effectively promote the expression of hair growth genes, and the hair growth genes can be the SCF gene. The protein encoded by the SCF gene is a cytokine known as hematopoietic stem cell factor (SCF). SCF plays important physiological roles in multiple tissues and organs, including regulating hair growth and hair follicle function. Cashew nut membrane extract has the ability to increase the expression of the SCF gene by approximately 1.08 times, thereby increasing the expression of hair growth-related genes in hair follicle cells. Therefore, cashew nut membrane extract is suitable for preparing a hair care composition that promotes the expression of hair growth genes.

[0058] In some embodiments, cashew nut membrane extract can effectively inhibit the expression of hair loss genes, which can be SRD5α1, SRD5α2, or a combination thereof. The 5α-reductase encoded by the SRD5α1 and SRD5α2 genes is involved in androgen metabolism, including the conversion of testosterone to the more active dihydrotestosterone. Excessive dihydrotestosterone is associated with androgen-related intrinsic hair loss (e.g., male pattern baldness). Due to the effects of dihydrotestosterone on hair follicles, it can cause hair apoptosis and shorten the growth cycle, thereby inhibiting hair follicle growth. It also promotes oil secretion from sebaceous glands, leading to hair loss and oily scalp. Cashew nut membrane extract has the ability to inhibit the expression of the SRD5α1 gene by approximately 0.75 times and the SRD5α2 gene by approximately 0.68 times, thereby reducing the expression of hair loss genes and improving hair follicle health. Therefore, cashew nut membrane extract is suitable for preparing a hair care composition that reduces the expression of hair loss genes.

[0059] In some embodiments, cashew nut membrane extract can effectively inhibit the expression of genes that cause hair loss, and the hair loss gene can be AR (androgen receptor). High AR activity, when combined with excessive dihydrotestosterone, can exacerbate the effects of androgens on hair follicles, leading to the suppression of hair follicle growth and thus inhibiting hair follicle growth. Cashew nut membrane extract has the ability to inhibit the AR gene by approximately 0.8 times, thereby reducing the expression of hair loss genes and improving hair follicle health. Therefore, cashew nut membrane extract is suitable for preparing hair care compositions that reduce the expression of hair loss genes.

[0060] In some embodiments, cashew nut membrane extract can effectively inhibit the expression of genes that cause hair loss, and the hair loss gene can be the TGF-β gene (encoding transforming growth factor-β). Under certain conditions, the TGF-β gene can inhibit hair growth, promote inflammation, and lead to hair loss and scalp inflammation. The certain conditions may include, but are not limited to, changes in androgen levels. Cashew nut membrane extract has the ability to inhibit the TGF-β gene by approximately 0.87 times, thereby reducing the expression of hair loss genes and improving hair follicle health. Therefore, cashew nut membrane extract is suitable for preparing a hair care composition that reduces hair loss genes.

[0061] In some embodiments, cashew nut membrane extract is used to prepare a composition for hair health. For example, the composition can be in the form of a capsule containing cashew nut membrane extract powder or a drink containing cashew nut membrane extract in liquid form. In some embodiments, a composition comprises a container and cashew nut membrane extract contained within the container. For example, the cashew nut membrane extract drink is a cashew beverage containing cashew nut membrane extract within the container.

[0062] In some embodiments, the aforementioned composition can be manufactured into enteral, parenteral, or oral dosage forms using techniques well known to those skilled in the art.

[0063] In some embodiments, enteral or oral administration may be, but is not limited to, tablets, troches, lozenges, pills, capsules, dispersible powders, granules, solutions, suspensions, emulsions, syrups, elixirs, slurries, or the like.

[0064] In some embodiments, when the aforementioned composition is an edible composition, the edible composition comprises a specific amount of cashew nut membrane extract, wherein the edible composition can be in the form of powder, granules, solution, colloid, or paste.

[0065] In some embodiments, the edible composition containing the cashew nut membrane extract can be a food product or a food additive.

[0066] In some embodiments, edible compositions containing cashew nut membrane extract can be beverages, fermented foods, bakery products, health foods, or dietary supplements. In some embodiments, edible compositions containing cashew nut membrane extract can further include an adjuvant. For example, the adjuvant can be maltodextrin, malic acid, sucralose, citric acid, fruit flavoring, honey flavoring, steviol glycosides, or combinations thereof. The type and amount of the adjuvant selected are within the professional expertise and routine skills of those skilled in the art.

[0067] In some embodiments, the food additive may be a seasoning, a sweetener, a flavoring, a pH adjuster, an emulsifier, a coloring agent, or a stabilizer.

[0068] In some embodiments, in the aforementioned composition, the daily intake of cashew nut membrane extract is 4 grams of liquid.

[0069] Unless otherwise noted, all experimental procedures in the following examples were performed at room temperature (25°C-30°C) and atmospheric pressure (1 atm). Statistical analyses were performed using Excel. Data are presented as mean ± standard deviation (SD), and differences between groups were analyzed using a Student's t-test. In the figures, "*" indicates a p-value less than 0.05, "**" indicates a p-value less than 0.01, and "***" indicates a p-value less than 0.001. The presence of more "*" indicates a more statistically significant difference.

[0070] Example 1: Preparation of cashew nut membrane extract

[0071] A. Materials:

[0072] 1. Cashew nut film (Origin: Vietnam).

[0073] 2. Secondary water, also known as RO water (Reverse Osmosis) or double-distilled water, hereinafter referred to as "water".

[0074] B. Preparation process:

[0075] 1. Heat water to 85±5°C, add cashew nutmeg, and soak in the 85±5°C water for 90 minutes to form a primary extract containing solids. The weight ratio of cashew nutmeg to water is 1:10.

[0076] 2. Filter the cooled primary extract through a 400-mesh filter to remove the solids (i.e., the extracted cashew membrane) to obtain a cashew membrane filtrate.

[0077] 3. Set the concentrator (Rotavapor R-100, BUCHI) to 60±5°C and concentrate the filtrate under reduced pressure. Concentration is stopped when the Brix value of the filtrate reaches 8.8±0.5°Bx, resulting in a cashew nut membrane concentrate.

[0078] 4. Add 0.23% malic acid to the cashew nut membrane concentrate to adjust the pH value of the cashew nut membrane concentrate to 3.2±0.5 to obtain a cashew nut membrane extract.

[0079] Example 2: Compound analysis test

[0080] A. Materials and Instruments:

[0081] 1. Nuclear Magnetic Resonance Spectrometer (NMR): 1D and 2D spectra were obtained using an Ascend 400 MHz spectrometer purchased from Bruker Co., Germany. Chemical shifts are expressed in δ (ppm).

[0082] 2. High-resolution liquid chromatography-mass spectrometry: Determination was performed using an ultra-high performance liquid chromatograph (Ultimate 3000 HPLC, purchased from Thermo Fisher Scientific) connected in tandem with a high-resolution orbitrap ion trap mass spectrometer (Q-EXACTIVE System with Ion Max Source, purchased from Thermo Fisher Scientific). The unit is m / z.

[0083] 3. Medium pressure liquid chromatography (MPLC): Rf+ was purchased from Teledyne ISCO, Lincoln, NE, USA.

[0084] 4. High Performance Liquid Chromatography (HPLC): The HPLC was a Hitachi chromaster 5260 series; the elution solvent delivery system was a Hitachi chromaster 5110; the column thermostat was a Hitachi chromaster 5310; the diode array detector (DAD) was a Hitachi chromaster 5430, with a detection wavelength of 280 nm.

[0085] 5. HPLC analysis column: Mightysil RP-18 GP 250 (250 x 4.6 mm, 5 μm, purchased from Kanto, Tokyo, Japan).

[0086] 6. Column Chromatography Filling Materials:

[0087] (1) Macroporous resin: Diaion HP-20, purchased from Mitsubishi Chemical Corporation, Japan.

[0088] (2) Normal phase silica gel: Merck Kieselgel 60, 40-63 μm, purchased from Merck, Germany, product number Art.9385.

[0089] (3) Reverse phase silica gel: Merck RP-18, 40-63 μm, was purchased from Merck, Germany, product number Art.0250.

[0090] 7. Thin-Layer Chromatography:

[0091] (1) Normal phase TLC aluminum sheet: thin layer chromatography sheet, coated with silica gel 60 F 254 (0.25 mm), purchased from Merck, Germany.

[0092] (2) Reverse phase TLC aluminum sheet: Thin layer chromatography sheet, coated with RP-18 F 254-S (0.25 mm), purchased from Merck, Germany.

[0093] 8.UV Lamp: UVP UVGL-25, wavelengths are 254nm and 365nm.

[0094] 9. Solvents: Methanol, n-butanol, methanol-d4 (deuterated 99.5%), deuterium oxide (deuterated >99.8%), and dimethyl sulfoxide-d6 (deuterated >99.9%) were purchased from Merck, Taiwan, China.

[0095] 10. Filter membrane: Polyvinylidene fluoride membrane filters (PVDF), pore size 0.22 μm, purchased from Millipore, USA.

[0096] 11. Sample: Cashew nut membrane extract prepared in Example 1.

[0097] B. Compound separation and structure identification process:

[0098] 1. 5 liters of the cashew nut membrane extract prepared in Example 1 were subjected to liquid-liquid partition extraction using n-butanol as the solvent, yielding 48.9 g of an n-butanol-soluble fraction (lipid-soluble component) and 156.3 g of a water-soluble fraction (water-soluble component). This separation of the lipid-soluble and water-soluble components of the cashew nut membrane extract obtained in Example 1 was performed. Bioassay-guided fractionation was employed during the separation and purification process.

[0099] 2. Take 40 g of the n-butanol-soluble fraction from step 1 and perform preliminary separation using Diaion HP-20 macroporous resin column chromatography, using 5 liters each of pure water, pure water-methanol (volume ratio 1:1), and methanol as eluents, to obtain three fractions (hereinafter referred to as the first fraction P1, the second fraction P2, and the third fraction P3).

[0100] 3. Take the first fraction P1 and re-separate it using reverse phase medium pressure liquid chromatography (RP-MPLC) to obtain various eluents. Here, the eluent is linearly eluted from water to methanol, the eluent time is 60 minutes, and the flow rate is 15 ml / min. The samples are then analyzed by reverse phase thin layer chromatography (reverse phase TLC aluminum sheet: thin layer chromatography sheet, coated with RP-18F 254-S (0.25 mm)) and the extracts with similar results were combined to obtain three sub-separation parts, as shown in FIG1 (hereinafter referred to as the fourth separation part P4, the fifth separation part P5, and the sixth separation part P6).

[0101] 4. The fifth separation portion P5 was purified by reverse phase-high performance liquid chromatography (methanol / water = 1 / 19) to obtain compound TCI-CsN-01. 1 H-NMR) analysis of its chemical structure confirmed that compound TCI-CsN-01 was gallic acid, as shown in Figure 2.

[0102] 5. The sixth fraction P6 was purified by reverse-phase high-performance liquid chromatography (methanol / water = 1 / 9) to obtain compounds TCI-CsN-11 and TCI-CsN-12. Compound TCI-CsN-11 was confirmed to be phloroglucinol, and TCI-CsN-12 was confirmed to be protocatechuic acid, as shown in Figures 6 and 7 .

[0103] 6. Separate the second fraction P2 and perform further separation using reversed-phase medium pressure liquid chromatography (RP-MPLC) to obtain multiple extracts. The eluent was linearly eluted from water to methanol over a 100-minute elution period at a flow rate of 15 ml / min. Subsequently, extracts with similar results were combined using reversed-phase thin-layer chromatography to obtain eight sub-fractions, as shown in FIG1 (hereinafter referred to as the seventh fraction P7, the eighth fraction P8, the ninth fraction P9, the tenth fraction P10, the eleventh fraction P11, the twelfth fraction P12, the thirteenth fraction P13, and the fourteenth fraction P14).

[0104] 7. The seventh fraction P7 was purified by reverse phase HPLC (methanol / water = 3 / 17) to obtain compound TCI-CsN-02. 1 H-NMR) analysis of its chemical structure confirmed that compound TCI-CsN-02 was gallocatechin, as shown in FIG3 .

[0105] 8. The tenth fraction P10 was purified by reverse phase HPLC (methanol / water = 3 / 7) to obtain compound TCI-CsN-07. Compound TCI-CsN-07 was confirmed to be epicatechin gallate, as shown in FIG4 .

[0106] 9. The eleventh fraction P11 was purified by reverse-phase HPLC (methanol / water = 2 / 3) to obtain compound TCI-CsN-13. TCI-CsN-13 is naringenin 7-O-(6″-O-p-coumaryl)-β-D-glucoside, as shown in Figure 8 .

[0107] 10. The thirteenth fraction P13 was purified by reverse phase HPLC (methanol / water = 1 / 1) to obtain compound TCI-CsN-05. 1 After H-NMR analysis of its chemical structure, compound TCI-CsN-05 was confirmed to be epicatechin coumarate through literature comparison, as shown in Figure 5.

[0108] The names and chemical structures of the aforementioned compounds are shown in Table 1 below.

[0109] Table 1

[0110] Example 3: Hair follicle cell antioxidant test

[0111] A. Materials and Instruments:

[0112] 1. Cell line: Human follicle dermal papilla cells (HFDPC), purchased from PromoCell, cell number C-12071, hereinafter referred to as HFDPC cells.

[0113] 2. Cell culture medium: Follicle Dermal Papilla Cell Growth Medium (purchased from PromoCell, product number C-26501).

[0114] 3. DCFH-DA reagent: prepared with DCFH-DA (2',7'-dichlorodihydrofluorescein diacetate) (purchased from Sigma, product number SI-D6883-50MG) and DMSO (purchased from Sigma, product number 472301).

[0115] 4. Preparation of 1X DPBS: Dilute 10X DPBS 10-fold with sterilized ddH2O.

[0116] 5. 100mM H2O2 aqueous solution: Mix H2O2 and 1X DPBS at a volume ratio of 1:88 and set aside.

[0117] 6. Trypsin: Prepare by diluting 10X trypsin (purchased from Gibco, product number 15400-054) with 9 times its volume of DPBS.

[0118] 7. Flow cytometer, model BD Accuri, purchased from BD company.

[0119] B. Test process:

[0120] 1. Plate HFDPC cells at 1 x 10 per well. 5 The cells were seeded at a density of 100 cells / well in a 6-well culture plate containing 2 ml of cell culture medium per well and cultured at 37°C for 24 hours. Here, HFDPC cells were divided into three experimental groups: blank group G01, control group G02, and experimental group.

[0121] 2. After 24 hours of incubation, each group was replaced with experimental culture medium. The experimental culture medium for the blank group G01 and the control group G02 was cell culture medium without cashew membrane extract or its compounds. The experimental culture medium for the experimental groups is shown in Tables 2 and 3. Each group was then incubated at 34°C for 1 hour.

[0122] Table 2

[0123] Table 3

[0124] 3. After 1 hour of treatment, DCFH-DA reagent was added to each group to a final concentration of 5 μg / mL, and each group was treated at 37°C for 15 minutes.

[0125] 4. After 15 minutes of treatment, add 5 μl / well of 100 mM H2O2 aqueous solution and treat at 34°C for 0.5 hours.

[0126] 5. Remove the experimental culture medium from each group after treatment and rinse twice with 1X DPBS.

[0127] 6. After rinsing, add 500 μl of trypsin to each well and incubate in the dark for 5 minutes. Afterward, add cell culture medium to terminate the reaction. Collect the suspended cells and cell culture medium from each well into a corresponding 1.5 ml microcentrifuge tube and centrifuge at 400 x g for 5 minutes to pellet the cells.

[0128] 7. Remove the supernatant from each centrifuge tube and wash the pelleted cells once with 1X DPBS. Centrifuge again at 400xg for 5 minutes. Remove the supernatant from each centrifuge tube again and add 200μl of 1X DPBS to each centrifuge tube to resuspend the cells.

[0129] 8. After setting the excitation light parameters of the flow cytometer to 450-490nm and the scattered light parameters to 510-550nm, the fluorescence signal of DCFH-DA in each group was measured by flow cytometry. Since DCFH-DA is first hydrolyzed into DCFH (dichlorodihydrofluorescein) after entering HFDPC cells, and then oxidized by reactive oxygen species (ROS) to DCF (dichlorofluorescein), which emits green fluorescence, the fluorescence intensity of HFDPC cells treated with DCFH-DA reflects the ROS content in CCD-996SK cells, and can thus determine the proportion of HFDPC cells with high ROS expression compared to the original cell population.

[0130] C. Test results:

[0131] The relative ROS production of all groups was calculated according to the following formula: relative ROS production (%) = (green fluorescence signal of each group / green fluorescence signal of blank group G01) × 100%.

[0132] Because the experiment was repeated three times, the results of the three replicates for each group were averaged to obtain the mean value. Statistically significant differences between the results of the control group G02 and the other groups were analyzed using a Student's t-test. In the figures, "*" indicates a p-value less than 0.05 when compared with the control group G02, "**" indicates a p-value less than 0.01 when compared with the control group G02, and "***" indicates a p-value less than 0.001 when compared with the control group G02.

[0133] See Figure 9. The blank group, G01, was not treated with cashew nut membrane extract or stimulated with H2O2. Therefore, the results for the blank group, G01, represent the performance of cells under normal physiological metabolic conditions. Here, assuming the relative ROS generation of the blank group, G01, is 100%, the relative ROS generation of the control group, G02, is 180.7%; the relative ROS generation of the experimental group, G30, is 65.8%, and the relative ROS generation of the experimental group, G32, is 53.5%. In other words, relative ROS generation in the control group, G02, increased by approximately 80.1% after H2O2 stimulation compared to the blank group, G01. In the experimental group, G30, after treatment with a lower concentration of cashew nut membrane extract and H2O2 stimulation, relative ROS generation significantly decreased by approximately 63.5% compared to the control group, G02. Furthermore, relative ROS generation in the experimental group decreased by approximately 34.2% compared to the blank group, G01 (ROS inhibition rates are shown in Table 4 below). Compared to the control group G02, experimental group G32, after adding a higher concentration of cashew nut membrane extract and then stimulating with H2O2, showed a significant reduction of approximately 70.4% in ROS production. Compared to the blank group G01, experimental group 1 showed a reduction of approximately 46.5% in ROS production (ROS inhibition rates are shown in Table 4 below).

[0134] Table 4

[0135] See Figure 10. The cells in the blank group, G01, were not treated with cashew nut membrane extract or stimulated with H2O2. Therefore, the experimental results for blank group G01 represent the performance of cells under normal physiological metabolic conditions. The relative ROS generation levels of each group are shown in Figure 10. The ROS inhibition rate (%) for each group was calculated using the formula: (ROS generation in control group G02 - ROS generation in blank group G01) - (ROS generation in experimental group - ROS generation in blank group G01) ÷ (ROS generation in control group G02 - ROS generation in blank group G01). The ROS inhibition rates for the experimental groups are shown in Table 5 below.

[0136] Table 5

[0137] This indicates that cashew nut membrane extract can significantly reduce ROS production in hair follicle cells caused by H₂O₂. H₂O₂ induces aerobic metabolism in cells, which in turn generates ROS. Intracellular ROS attack macromolecules such as proteins, nucleic acids, and lipids, causing cellular damage. In other words, the experiment demonstrates that cashew nut membrane extract and its compounds enhance the antioxidant capacity of hair follicle cells and reduce damage to them. Cashew nut membrane extract has the effect of enhancing antioxidant activity and reducing cellular damage.

[0138] Example 4: Test to promote hair follicle cell proliferation

[0139] A. Materials and Instruments:

[0140] 1. Detection kit: Cell proliferation detection reagent kit (Click-iT TM Plus EdU Flow Cytometry Assay Kits-Alexa Fluor TM 488 picolyl azide, 50 tests) was purchased from Invitrogen, product number C10632.

[0141] 2. Flow cytometer (purchased from BD, product number BD Accuri).

[0142] B. Test process:

[0143] 1. Plate HFDPC cells at 1×10 per well 5 The cells were seeded at a density of 100 cells / well in a 6-well culture dish and cultured at 5% CO2 and 37°C until the cells reached 80% to 90% confluence. Here, HFDPC cells were divided into various groups as shown in Tables 6 and 7.

[0144] Table 6

[0145] Table 7

[0146] 2. After 24 hours of culture, the DNA content of each group was measured using a cell proliferation assay kit. After treating each group of cells according to the protocol provided in the cell proliferation assay kit, the flow cytometer was set to an excitation wavelength of 450-490 nm and a scattered light wavelength of 510-550 nm. The fluorescence signal of EdU (5-ethynyl-2'-deoxyuridine) in each group was measured using a flow cytometer.

[0147] C. Test results:

[0148] The DNA content of each group was used as the basis for analyzing the hair follicle cell proliferation rate of each group. The relative hair follicle cell proliferation rate of all groups was calculated according to the following formula: relative hair follicle cell proliferation rate (%) = (fluorescence signal of each group / fluorescence signal of blank group G01) × 100%.

[0149] Statistically significant differences between the results of the blank group G01 and the other groups were determined using the Student's t-test. In the figures, "*" indicates a p-value less than 0.05 compared to the blank group G01, "**" indicates a p-value less than 0.01 compared to the blank group G01, and "***" indicates a p-value less than 0.001 compared to the blank group G01.

[0150] Please refer to Figure 11. The blank group, G01, was not treated with cashew nut membrane extract. Therefore, the experimental results for the blank group, G01, represent the performance of HFDPC cells under normal physiological metabolic conditions. Here, assuming the relative hair follicle cell proliferation rate of the blank group, G01, is 100%, the relative hair follicle cell proliferation rate of the control group, G02, is 138.8%; the relative hair follicle cell proliferation rate of the experimental group, G30, is 114.6%; and the relative hair follicle cell proliferation rate of the experimental group, G32, is 86.9%. This indicates that, compared to the blank group, G01, the relative hair follicle cell proliferation rate of the control group, G02, significantly increased by approximately 38.8% after the addition of 20% fetal bovine serum. Compared to the blank group, the relative hair follicle cell proliferation rate of the experimental group, G30, significantly increased by approximately 14.6% after the addition of 0.125% cashew nut membrane extract.

[0151] Please refer to Figure 12. The blank group, G01, was not treated with cashew nut membrane extract. Therefore, the experimental results for the blank group, G01, represent the performance of HFDPC cells under normal physiological metabolic conditions. Here, assuming the relative hair follicle cell proliferation rate of the blank group, G01, is 100%, the relative hair follicle cell proliferation rate of the control group, G02, is 118.8%; the relative hair follicle cell proliferation rate of the experimental group, G34, is 83.7%; the relative hair follicle cell proliferation rate of the experimental group, G36, is 93.5%; the relative hair follicle cell proliferation rate of the experimental group, G38, is 89.9%; the relative hair follicle cell proliferation rate of the experimental group, G40, is 114.1%; the relative hair follicle cell proliferation rate of the experimental group, G42, is 127.9%; the relative hair follicle cell proliferation rate of the experimental group, G44, is 109.6%; and the relative hair follicle cell proliferation rate of the experimental group, G46, is 125%. In other words, compared to the blank control group G01, the HFDPC cells in the control group G02 significantly increased their relative hair follicle cell proliferation rate by approximately 18.8% after adding 20% ​​fetal bovine serum. Compared to the blank control group G01, experimental groups G34-38 showed no significant difference; however, experimental groups G40-46 showed significant increases in relative hair follicle cell proliferation rates of approximately 14.1%, 27.9%, 9.6%, and 25%, respectively.

[0152] The experimental results show that 0.125% cashew nut membrane extract and experimental groups G40-G46 significantly promoted the proliferation of hair follicle cells. Furthermore, experimental groups G42 and G46 significantly increased the rate of hair follicle cell proliferation compared to the control group G02. In other words, the experiments demonstrate that cashew nut membrane extract and its compounds can promote hair follicle cell proliferation, thereby promoting hair growth and, therefore, be used for hair health.

[0153] Example 5: Cashew nut membrane extract test on the expression of genes related to hair health

[0154] A. Materials and Instruments:

[0155] 1. RNA extraction reagent kit was purchased from Genemark.

[0156] 2. III reverse transcriptase was purchased from Invitrogene.

[0157] 3. ABI StepOnePlus™ Real-Time PCR system, purchased from Thermo Fisher Scientific.

[0158] 4. KAPA SYBR FAST qPCR Master Mix (2X) Kit, purchased from KAPA Biosystems, product number KK4600.

[0159] B. Test process:

[0160] HFDPC cells were plated at 1×10 5 The cells were seeded at a density of 1000 cells / well in a 6-well culture plate with 2 mL of culture medium per well and cultured at 37°C for 24 h.

[0161] After incubation, HFDPC cells were divided into several blank groups (G01) and experimental groups to compare the expression of different genes. The culture medium of the blank group (G01) contained no extract, while the culture medium of the experimental groups (G30 and G32) contained either 0.125% or 0.25% of the cashew nut membrane extract prepared in Example 1. The cells were then incubated at 37°C for 6, 24, and 48 hours.

[0162] The culture medium of the blank group G01 and the experimental groups with different concentrations was removed and rinsed with PBS.

[0163] After rinsing, the cell membrane of each group of HFDPC cells was broken using the cell lysis solution of the RNA extraction reagent kit to form a cell solution.

[0164] RNA was extracted from the cell solution of each group using an RNA extraction reagent kit.

[0165] 2000 ng of extracted RNA was used as template in each group. III reverse transcriptase reverse transcribes the extracted RNA into the corresponding cDNA.

[0166] Using ABI StepOnePlus TMA quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was performed on the cDNA using the KAPA SYBR FAST qPCR Master Mix (2X) Kit and the primer combinations listed in Table 8. Expression levels of various target genes and their melting curves were observed in the control group (G01) and the experimental group (HFDPC). The qRT-PCR instrument settings were 95°C for 20 seconds, 95°C for 3 seconds, and 60°C for 30 seconds, repeated for 40 cycles.

[0167] Use 2 -ΔΔCt Methods The relative expression level of the target gene was determined. The relative expression level is defined as the fold change of the RNA expression level of the target gene in the experimental group relative to the RNA expression level of the same gene in the blank group G01. -ΔΔCt Methods The cycle threshold of TBP gene was used as the cycle threshold of reference gene for internal control (Ct), and the fold change was calculated according to the following formula: △Ct = Ct target gene of experimental group / Ct target gene of blank group G01 GAPDH △△Ct=△Ct 实验组之目标基因 -△Ct blank group G01 target gene fold change = 2 -ΔΔCt平均值

[0168] The standard deviation of the relative expression level was calculated using STDEV in Excel. Statistically significant differences between the results of the blank group G01 and the other groups were analyzed using the Student's t-test. In the figures, "*" indicates a p-value less than 0.05 compared to the blank group G01, "**" indicates a p-value less than 0.01 compared to the blank group G01, and "***" indicates a p-value less than 0.001 compared to the blank group G01.

[0169] Table 8 below shows the relevant sequences of the related gene expression experiments.

[0170] Table 8

[0171] Statistically significant differences between the measurement results of the blank group G01 and the experimental group were determined using a Student's t-test. (In the figure, "*" indicates a p-value less than 0.05 compared to the blank group G01, "**" indicates a p-value less than 0.01 compared to the blank group G01, and "***" indicates a p-value less than 0.001 compared to the blank group G01. The more "*" there are, the more statistically significant the difference is.)

[0172] Please refer to Figures 13 and 14 for the gene expression results after 6 hours of culture. In the blank group, G01, HFDPC cells were not treated in any way, meaning they were under normal physiological metabolic conditions, and their gene expression levels were set to 1.0. The expression levels of the SRD5α1 gene in the SRD5α1 gene experimental group were -0.49-fold and -0.54-fold higher than those in the blank group, G01, respectively. The expression levels of the SRD5α2 gene in the SRD5α2 gene experimental group were 3.4-fold and 3.65-fold higher than those in the blank group, G01, respectively. The expression levels of the AR gene in the AR gene experimental group were 1.04-fold and 1.3-fold higher than those in the blank group, G01, respectively. The expression levels of the KROX20 gene in the KROX20 gene experimental group were 1.93-fold and 1.85-fold higher than those in the blank group, G01, respectively. The expression levels of the SCF gene in the SCF gene experimental group were 1.08-fold and 1.05-fold higher than those in the blank group, G01, respectively. The expression levels of the VEGF gene in the VEGF gene experimental group were 1.16-fold and 1.26-fold higher than those in the blank group, G01, respectively. The expression levels of IGF1 gene in the IGF1 gene experimental group were 1.49 times and 1.5 times that of the blank group G01, while the expression levels of TGF-β gene in the TGF-β gene experimental group were -0.87 times and -0.85 times that of the blank group G01.

[0173] Please refer to Figures 15 and 16 for the results of gene analysis after 24 hours of culture. In the blank group, G01, HFDPC cells were not treated in any way, meaning they were under normal physiological metabolic conditions, and their gene expression levels were set at 1.0. The expression levels of the SRD5α1 gene in the SRD5α1 gene experimental group were -0.73 and -0.75 times that of the blank group, G01, respectively. The expression levels of the SRD5α2 gene in the SRD5α2 gene experimental group were 1.02 and 1.12 times that of the blank group, G01, respectively. The expression levels of the AR gene in the AR gene experimental group were 1.29 and 1.43 times that of the blank group, G01, respectively. The expression levels of the KROX20 gene in the KROX20 gene experimental group were 1.01 and 1.04 times that of the blank group, G01, respectively. The expression levels of the SCF gene in the SCF gene experimental group were -0.73 and -0.665 times that of the blank group, G01, respectively. The expression levels of the VEGF gene in the VEGF gene experimental group were -0.89 times and -0.93 times that of the blank group G01. The expression levels of the IGF1 gene in the IGF1 gene experimental group were -0.76 times and -0.7 times that of the blank group G01. The expression levels of the TGF-β gene in the TGF-β gene experimental group were -0.76 times and -0.7 times that of the blank group G01.

[0174] Please refer to Figures 17 and 18 for the results of gene analysis after 48 hours of culture. In the blank group, G01, HFDPC cells were not treated in any way, meaning they were under normal physiological metabolic conditions, and their gene expression levels were set at 1.0. The expression levels of the SRD5α1 gene in the SRD5α1 gene experimental group were -0.75-fold and -0.76-fold, respectively, compared to the blank group, G01. The expression levels of the SRD5α2 gene in the SRD5α2 gene experimental group were 1.2-fold and -0.68-fold, respectively, compared to the blank group, G01. The expression levels of the AR gene in the AR gene experimental group were -0.8-fold and -0.77-fold, respectively, compared to the blank group, G01. The expression levels of the KROX20 gene in the KROX20 gene experimental group were -0.98-fold and -0.93-fold, respectively, compared to the blank group, G01. The expression levels of the SCF gene in the SCF gene experimental group were -0.6-fold and -0.68-fold, respectively, compared to the blank group, G01. The expression levels of the VEGF gene in the VEGF gene experimental group were -0.77 times and -0.91 times that of the blank group G01. The expression levels of the IGF1 gene in the IGF1 gene experimental group were -0.72 times and -0.61 times that of the blank group G01. The expression levels of the TGF-β gene in the TGF-β gene experimental group were -0.8 times and -0.78 times that of the blank group G01.

[0175] The statistical differences of hair health-related genes and the blank group G01 are shown in Table 9 below.

[0176] Table 9

[0177] Note: SRD5α1, SRD5α2, AR and TGF-β are genes related to hair loss; KROX20 and SCF are genes related to hair growth; VEGF and IGF1 are genes related to angiogenesis.

[0178] It can be seen that cashew nut membrane extract can significantly inhibit the expression of SRD5α1 gene, SRD5α2 gene, AR gene and TGF-β gene; significantly increase the expression of KROX20 gene and SCF gene; and significantly increase the expression of VEGF gene and IGF1 gene. This shows that cashew nut membrane extract increases hair follicle angiogenesis, promotes the delivery of hair growth nutrients, enhances hair follicle formation, and thus improves hair follicle health. It can also reduce scalp oiliness, reduce hair loss, reduce inflammation, and reduce hair loss caused by scalp inflammation, thereby improving hair follicle health.

[0179] Example 6: Human Trial - Blood Test

[0180] A.Test process:

[0181] Seven healthy adult subjects aged 20 and above, not taking any medications or supplements for hair loss prevention, but experiencing hair loss, were asked to consume a 50 ml bottle of a test drink daily for 12 consecutive weeks (84 days). The test drink contained 4 ml of the cashew nut membrane extract prepared in Example 1, with the remainder being water. Blood was drawn from the subjects at weeks 0, 8, and 12 to measure changes in malondialdehyde (MDA), an antioxidant marker, before and after consumption of the cashew nut membrane extract.

[0182] In this embodiment, the concentration of malondialdehyde, an antioxidant indicator in the blood of the subjects, was tested by an outsourcing agency, and the outsourcing agency referred to relevant blood test standards.

[0183] B. Test results:

[0184] Statistically significant differences between the results at Weeks 0, 8, and 12 were determined using the Student's t-test. In the figures, "*" indicates a p-value less than 0.05 compared to Week 0, "**" indicates a p-value less than 0.01 compared to Week 0, and "***" indicates a p-value less than 0.001 compared to Week 0.

[0185] Please refer to Figure 19. At week 0, the subjects' blood malondialdehyde concentration, an antioxidant indicator, was approximately 1.47 μg / mL. At week 8 (i.e., after 8 weeks of continuous consumption of cashew nut membrane extract), the subjects' blood malondialdehyde concentration significantly decreased to approximately 1.31 μg / mL. At week 12 (i.e., after 12 weeks of continuous consumption of cashew nut membrane extract), the subjects' blood malondialdehyde concentration decreased to approximately 0.95 μg / mL. In other words, compared to before taking the drug, the continuous consumption of cashew nut membrane extract for 8 weeks can reduce the blood malondialdehyde concentration of these subjects by 11.4%; the continuous consumption of cashew nut membrane extract for 12 weeks can reduce the blood malondialdehyde concentration of these subjects by 35.6%. Moreover, the improvement rate of the number of people reached 100%. This indicates that cashew nut membrane extract can reduce blood MDA concentration, enhance the body's antioxidant capacity, thereby reducing hair follicle cell damage and improving hair follicle health.

[0186] Example 7: Human body test - hair diameter detection

[0187] A.Test process:

[0188] Seven healthy adults aged 20 and above, not taking any medications or supplements for hair loss prevention, but experiencing hair loss, were asked to consume a 50 ml bottle of a test drink daily for 12 consecutive weeks (84 days). The test drink contained 4 ml of the cashew nut membrane extract prepared in Example 1, with the remainder being water. Hair diameter measurements were also performed at weeks 0, 8, and 12 to measure changes in hair diameter before and after taking the cashew nut membrane extract.

[0189] This example uses an ASG-300 / API-100 scalp analyzer, purchased from Aram Huvis in South Korea, for testing. Measurements are in millimeters (mm). The test method involves measuring the diameter of a hair at approximately 1 cm from the root at the same location on the top of the head, and then taking the average of 3-5 individual hairs.

[0190] B. Test results:

[0191] Statistically significant differences between the results at Weeks 0, 8, and 12 were determined using the Student's t-test. In the figures, "*" indicates a p-value less than 0.05 compared to Week 0, "**" indicates a p-value less than 0.01 compared to Week 0, and "***" indicates a p-value less than 0.001 compared to Week 0.

[0192] Please refer to Figure 20. The hair diameter of the subjects at week 0 was approximately 0.054 mm, the hair diameter of the subjects at week 8 (i.e., after taking cashew nut membrane extract for 8 weeks), was approximately 0.073 mm, and the hair diameter of the subjects at week 12 (i.e., after taking cashew nut membrane extract for 12 weeks), was approximately 0.081 mm. In other words, compared to before taking the drug, the hair diameter of these subjects increased significantly by 35.2% after taking the cashew nut membrane extract for 8 weeks; the hair diameter of these subjects increased significantly by 50% after taking the cashew nut membrane extract for 12 weeks. Moreover, the improvement rate reached 100%. This shows that cashew nut membrane extract can indeed increase the hair diameter of the subjects, increase hair stability, and improve hair follicle health.

[0193] Industrial Applicability

[0194] In summary, the cashew nut membrane extract of any embodiment is obtained by extracting the cashew nut membrane with a solvent, and can be used to prepare a hair care composition, thereby providing a composition that, when applied to an individual, can produce a hair care effect on that individual. In other words, the aforementioned composition has a hair care function. In some embodiments, the composition prepared from the cashew nut membrane extract further has one or more of the following functions: improving the antioxidant capacity of hair follicle cells, increasing hair follicle angiogenesis, promoting the expression of hair growth genes, reducing the expression of hair loss genes, and increasing hair diameter.

[0195] Of course, the present invention may have many other embodiments. Without departing from the spirit and essence of the present invention, those skilled in the art may make various corresponding changes and modifications based on the present invention, but these corresponding changes and modifications should all fall within the scope of protection of the claims of the present invention.

Claims

1. A use of a cashew nut (Anacardium occidentale) membrane extract for preparing a hair care composition, wherein the cashew nut membrane extract is prepared by extracting cashew nut membrane.

2. The use as claimed in claim 1, wherein in the extraction step, the solid-liquid ratio of the cashew nut membrane to the solvent is 5 to 20:1 to 5, the extraction temperature is 80° C. to 90° C., and the extraction time is 80 minutes to 120 minutes.

3. The use as claimed in claim 1, wherein the cashew nut membrane extract has the ability to increase the health of hair follicles.

4. The use as claimed in claim 3, wherein the cashew membrane extract increases the health of hair follicles by improving the antioxidant capacity of hair follicle cells.

5. The use according to claim 4, wherein the cashew nut membrane extract is at least one compound selected from the group consisting of epicatechin coumarate, phloroglucinol, protocatechuic acid and naringenin 7-O-(6"-O-p-coumaryl)-β-D-glucoside.

6. The use as claimed in claim 3, wherein the cashew membrane extract increases the health of the hair follicles by promoting the proliferation of hair follicle cells.

7. The use according to claim 6, wherein the cashew nut membrane extract is at least one compound selected from the group consisting of epicatechin coumarate, phloroglucinol, protocatechuic acid and naringenin 7-O-(6"-O-p-coumaryl)-β-D-glucoside.

8. The use as claimed in claim 3, wherein the cashew nut membrane extract increases the health of hair follicles by increasing angiogenesis of hair follicles.

9. The use as claimed in claim 3, wherein the cashew membrane extract increases the health of the hair follicles by promoting the expression of hair growth genes.

10. The use as claimed in claim 3, wherein the cashew nut membrane extract increases the health of the hair follicles by reducing the expression of hair loss genes.

11. The use as claimed in claim 3, wherein the cashew nut membrane extract increases the health of the hair follicles by reducing blood MDA concentration.

12. The use according to claim 1, wherein the cashew nut membrane extract has the ability to increase hair diameter.

Citation Information

Patent Citations

  • Composition and method for promoting hair growth

    CN103445971A

  • Application of procyanidine to preparing medicine for preventing or treating alopecia caused by chemotherapies

    CN104857177A

  • Botanical extract skin care

    CN112638179A

  • Use of tea polyphenol for preparing medicine for preventing and treating lipsotrichia induced from chemotherapy

    CN1640393A

  • Hair-growing agent composition

    JP2001220320A